Trial Profile
A Multicenter, Double-Blind, Randomized, 12-Month, Placebo-Controlled Study to Evaluate the Lipid-Lowering Effect, Safety and Tolerability of AVE5530 25 mg/Day and 50mg/Day When Added to Ongoing Stable Statin Therapy (HMG-CoA Reductase Inhibitors) in Patients With Primary Hypercholesterolaemia.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Canosimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 24 Dec 2021 This trial has been completed in Czechia (global end date 2009-06-17) as per European Clinical Trials Database
- 06 Oct 2021 This trial has been completed in France and Spain (global end date 2009-06-17) as per European Clinical Trials Database
- 28 Apr 2012 Additional trial location (Portugal) identified as reported by EudraCT.